David Mak, MD

PGY-5 Radiation Oncology
@UofTDRO @Sunnybrook @pmcancercentre | MD @UBCmedicine

[Radiation Oncology @UofTDRO]

🎓Hats off to our @UofTDRO Class of 2024 Post-Graduate Trainees for their outstanding achievements and hard work! We know you'll make a positive impact on the world. #UofTGrad24
🎉Explore the list of graduands and award winners: https://t.co/Hp9FVxXiER
@ldawsonmd

[Amir Safavi @safaviaa]

❤️ to @RissaSherwood @BadrIdsaid @davidymak, my @UofTDRO co-residents & friends for life. You make the world a better place & excited for next steps after grad! 🌊🤠🗽👶🏻

🙏 @DrAlexLouie & @DrBezjakRO, dear #radonc mentors @Sunnybrook & @RadMedPM

📸: fellow grad @MarcBarcieMD!

[Alex Louie MD, PhD @DrAlexLouie]

Uncovering the armpit of SBRT - in this 🌎's first case series reported from @Sunnybrook - we describe our teams experience for the unique target of axillary 🦾metastases #radonc ☢️⚡️ https://t.co/1XjjxQc1g6

[Radiation Oncology @UofTDRO]

Congrats to our @UofTDRO PGY5 residents Badr Id Said, David Mak, Amir Safavi, and Marissa Sherwood for passing their Royal College oral exams. Thanks to all who supported them on this journey. Join us on June 10, 2024, for the #UTDRO Graduation ceremony! @ldawsonmd @uoftmedicine

[Sympascho Young MD @DrSymYoung]

@drviviantan presenting 5-year clinical outcomes for patients with solitary vs bilateral kidneys treated with SBRT at #ASTRO2023. SBRT safe and effective for RCC, even with solitary kidneys. 👏👏Compelling study!! @DrCorreaRO @_ShankarSiva @DrAlexLouie

[Vivian Tan MD @drviviantan]

#ASPIRE-ILD for #SABR in ILD 🫁 presented at #ASTRO2023 @drdavidpalma @DrAlexLouie @HoudaBahig #radonc #onctwitter
✅ 50Gy/5#, 1 year OS 79%, met toxicity thresholds

[IJROBP - The Red Journal @IJROBP]

The new OncoScan is populated by IROCK stars! 😎
"Radiation Therapy for Renal Cell Carcinoma" - what to know about renal masses, how to SBRT them, +/- systemic therapy.
🥷Who says we don't have new indications?🥷
@NicholasZaorsky @DrAlexLouie @_ShankarSiva
https://t.co/28NUKseZpG

[Justin Z. Wang @justinzw]

Another Canadian collaborative study, thanks to @FarshadNassiri @gelarehzadeh @ap_landry @detsang @afgao
and @Sty_md @SunnyD_UT @DrMDCusimano @AlexRebchuk Serge Makarenko, David Munoz, Julian Spears @UHN @UofTNeuroSurge @UBC @UnityHealthTO

https://t.co/Ylx1pIg10O

[Amir Safavi @safaviaa]

60F w/ EGFR+ (Ex21) synch oligomet NSCLC #lcsm: 1.5 cm 🫁 primary, 0.4 cm asymp 🧠 met, painful 🦴met. To start Osi. #radonc consulted.

🧐 What would @DrBezjakRO and I (@UofTDRO @RadMedPM) do?

🗣️ Hammer Wisely ☢️🔨🦀!

Now in @ASTRO_org @IJROBP #gyzone: https://t.co/MYcH5QW0bf

[SIOP International @WorldSIOP]

📢 We're thrilled to announce that Derek Tsang, a renowned radiation oncologist, will be attending #SIOPcongress in Canada.
🗓️ Don't miss his lecture on cutting-edge advancements in #radiotherapy. Save the date!

➡️ https://t.co/sdZKKxDaNk

@detsang #RadiationOncology

[David Kirsch, MD, PhD @DKirschMDPhD]

Fun to meet amazing @UTDRO #radonc residents at the @BlueJays game today. Bonus to chat with @ldawsonmd about @RadMedPM @pmcancercentre @UHN and @JoannaJavor about the critical role CSRTs can play in caring for cancer patients in #radonc

[Amir Safavi @safaviaa]

.@UTDROResidents had a ⚾️ at the @BlueJays game with our @RadMedPM friends! Can’t wait for the next social 😊 @ldawsonmd @DKirschMDPhD @JoannaJavor @davidymak @_inhwakim @UofTDRO

[Dr. Glaucomflecken @DGlaucomflecken]

For those who don’t match this week…

[Med Phys Papers @medphyspapers]

R&O: "Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial" https://t.co/bidbquTT2U

[Amir Safavi @safaviaa]

Excellent 🏀 outing for the @UTDROResidents #radonc PAs and fellows courtesy of @RadMedPM, with a shoutout on the jumbotron for our @pmcancercentre group!

[Vivian Tan MD @drviviantan]

Published “Top 10 Lessons Learned from Trials in Oligometastatic Cancers” in CRT reviewing #SABR outcomes, toxicity, costs, combination with systemic therapies and barriers to accrual for trials
@drdavidpalma #radonc #onctwitter #medtwitter
https://t.co/RK8pBBRPZ4

[Drew Moghanaki @DrewMoghanaki]

Radiosurgery for Refractory Depression likely saved the lives of patients who participated in this IRB-approved clinical trial. Treatment target = bilateral anterior limb of the internal capsule) #radonc https://t.co/XRuArV3U4j

[PDBrown @PDBrownOnc]

Landmark trial RTOG1205 reirradiation recurrent #GBM
•Small GTVs 18 cc
•80% 1st relapse
•Significant PFS benefit, important clinically if options limited
•No OS benefit possibly due to salvage RT on Bev alone arm
•Link:
https://t.co/hGobIHmGRT

#roedu

[Drew Moghanaki @DrewMoghanaki]

@davidymak @JTOonline @DrAlexLouie @mctjong @Sunnybrook David, I'm glad you highlighted the benefits of adding RT to osimertinib to improve survival. Something that occurs less often when adding other drugs to osimertinib. @jillfeldman4 @ivybelkins @JackWestMD @n8pennell @DrJNaidoo @CharuAggarwalMD @RamalingamMD